Blueprint Medicines Corporation (0HOJ.L)
USD 101.7
(4.02%)
USD 101.7
(4.02%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 722.86 Million USD | -1.73% |
| 2022 | 723.74 Million USD | -10.0% |
| 2021 | 804.12 Million USD | 65.94% |
| 2020 | 484.6 Million USD | 13.27% |
| 2019 | 427.83 Million USD | 46.75% |
| 2018 | 291.54 Million USD | 68.84% |
| 2017 | 172.67 Million USD | 72.07% |
| 2016 | 100.34 Million USD | 59.17% |
| 2015 | 63.04 Million USD | 58.67% |
| 2014 | 39.73 Million USD | 89.21% |
| 2013 | 21 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 175.22 Million USD | 3.08% |
| 2024 Q1 | 166.93 Million USD | -4.76% |
| 2024 Q2 | 169.99 Million USD | 1.83% |
| 2023 Q4 | 175.27 Million USD | -3.16% |
| 2023 FY | 711.19 Million USD | -1.73% |
| 2023 Q1 | 184.31 Million USD | 0.32% |
| 2023 Q2 | 183.22 Million USD | -0.59% |
| 2023 Q3 | 180.99 Million USD | -1.22% |
| 2022 Q1 | 163.45 Million USD | -60.67% |
| 2022 FY | 723.74 Million USD | -10.0% |
| 2022 Q2 | 189.29 Million USD | 15.81% |
| 2022 Q4 | 183.73 Million USD | -1.88% |
| 2022 Q3 | 187.25 Million USD | -1.08% |
| 2021 Q4 | 415.6 Million USD | 202.27% |
| 2021 Q1 | 121.71 Million USD | 1.47% |
| 2021 Q2 | 129.31 Million USD | 6.25% |
| 2021 Q3 | 137.49 Million USD | 6.33% |
| 2021 FY | 804.12 Million USD | 65.94% |
| 2020 FY | 484.6 Million USD | 13.27% |
| 2020 Q4 | 119.94 Million USD | 7.47% |
| 2020 Q3 | 111.6 Million USD | -16.25% |
| 2020 Q2 | 133.25 Million USD | 11.23% |
| 2020 Q1 | 119.8 Million USD | -0.92% |
| 2019 Q2 | 109.02 Million USD | 20.07% |
| 2019 Q3 | 107.1 Million USD | -1.76% |
| 2019 Q4 | 120.91 Million USD | 12.9% |
| 2019 FY | 427.83 Million USD | 46.75% |
| 2019 Q1 | 90.8 Million USD | 7.87% |
| 2018 Q1 | 59.86 Million USD | 15.75% |
| 2018 Q2 | 70.9 Million USD | 18.44% |
| 2018 Q3 | 76.6 Million USD | 8.03% |
| 2018 Q4 | 84.17 Million USD | 9.88% |
| 2018 FY | 291.54 Million USD | 68.84% |
| 2017 Q3 | 46.67 Million USD | 16.39% |
| 2017 Q2 | 40.1 Million USD | 17.37% |
| 2017 Q1 | 34.17 Million USD | 17.57% |
| 2017 FY | 172.67 Million USD | 72.07% |
| 2017 Q4 | 51.72 Million USD | 10.8% |
| 2016 Q4 | 29.06 Million USD | 26.13% |
| 2016 Q3 | 23.04 Million USD | -11.24% |
| 2016 Q2 | 25.96 Million USD | 16.52% |
| 2016 FY | 100.34 Million USD | 59.17% |
| 2016 Q1 | 22.28 Million USD | 11.09% |
| 2015 Q3 | 15.9 Million USD | 5.44% |
| 2015 FY | 63.04 Million USD | 58.67% |
| 2015 Q2 | 15.08 Million USD | 25.67% |
| 2015 Q4 | 20.05 Million USD | 26.11% |
| 2015 Q1 | 12 Million USD | -16.03% |
| 2014 FY | 39.73 Million USD | 89.21% |
| 2014 Q1 | 6.95 Million USD | 0.0% |
| 2014 Q3 | 10.28 Million USD | 25.49% |
| 2014 Q4 | 14.29 Million USD | 38.93% |
| 2014 Q2 | 8.19 Million USD | 17.92% |
| 2013 FY | 21 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | -192.297% |
| Dynavax Technologies Corporation | 219.14 Million USD | -229.855% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -407.403% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 98.22% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -36.644% |
| Perrigo Company plc | 1.52 Billion USD | 52.708% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -162.198% |
| Illumina, Inc. | 3.81 Billion USD | 81.042% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 92.95% |
| Nektar Therapeutics | 190.9 Million USD | -278.654% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -60.282% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 64.79% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -499.104% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -1518.333% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 58.606% |
| Waters Corporation | 943.51 Million USD | 23.387% |
| Biogen Inc. | 5.2 Billion USD | 86.112% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -216.102% |
| Adicet Bio, Inc. | 152.03 Million USD | -375.448% |
| Evolus, Inc. | 189.75 Million USD | -280.936% |
| bluebird bio, Inc. | 240.23 Million USD | -200.901% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -5853.884% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -165.858% |
| FibroGen, Inc. | 398.11 Million USD | -81.572% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 65.822% |
| Homology Medicines, Inc. | 9.87 Million USD | -7220.111% |
| Geron Corporation | 70.44 Million USD | -926.194% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 59.842% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -5096.834% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -69.031% |
| Myriad Genetics, Inc. | 600.1 Million USD | -20.457% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 74.324% |
| OPKO Health, Inc. | 574.68 Million USD | -25.784% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -616.932% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -31.056% |
| Zoetis Inc. | 2.76 Billion USD | 73.857% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -1390.374% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 33.645% |
| Exelixis, Inc. | 1.58 Billion USD | 54.445% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 84.862% |
| uniQure N.V. | 285.08 Million USD | -153.559% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -1746.247% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1196.472% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -51.747% |
| Verastem, Inc. | 92.08 Million USD | -685.002% |
| Imunon, Inc. | 21.03 Million USD | -3337.215% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 7.276% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 46.88% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 54.722% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -96.103% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -141.503% |
| TG Therapeutics, Inc. | 198.47 Million USD | -264.208% |
| Insmed Incorporated | 949.26 Million USD | 23.85% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -76.823% |
| Incyte Corporation | 1.19 Billion USD | 39.281% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 30.76% |